Nepedia
Back to Discover
Advanced Reader
🧬

Pharmacogenomics

life science Maturity 11-13 Next article →

Pharmacogenomics, often called PGx, is a scientific field that studies how a person's genome affects their response to drugs. The name comes from combining pharmacology, the study of drugs, with genomics, the study of genes. This science examines how both inherited and acquired genetic variations change how a person reacts to medication. By looking at DNA mutations, such as point mutations or copy number variations, researchers can predict how a patient will respond to a treatment. The ultimate goal is to move away from a "one-dose-fits-all" approach to medicine. Instead, scientists aim to develop precision medicine, where treatments are optimized for an individual's unique genetic makeup.

To understand this process, we must look at pharmacokinetics, which describes how the body handles a drug. This involves four main steps: absorption, distribution, metabolism, and elimination. These processes are often managed by enzymes, such as drug metabolizing enzymes, or by drug transporters. Genetic variations in the DNA loci that produce these proteins can change their activity. For example, a person might have an increase, a decrease, or a total loss of function in a specific enzyme. If these proteins do not work correctly, the amount of medication in the body may change. This can cause a drug to fall outside the therapeutic window, leading to either a loss of effectiveness or dangerous toxicity.

Drug-metabolizing enzymes are a critical part of this mechanism. A very important group is the cytochrome P450 enzyme family. This family is responsible for the metabolism of 70% to 80% of all medications used in clinical settings. Within this group, enzymes like CYP3A4, CYP2C9, CYP2C19, and CYP2D6 are highly polymorphic, meaning they vary greatly between people. Other enzymes, such as UGT1A1, DPYD, and TPMT, also play roles in how drugs are processed. Additionally, drug transporters like the solute carrier or ATP-binding cassette help move medications across cellular membranes. These transporters move drugs between body fluid compartments, such as the blood, gut lumen, or the brain.

Pharmacogenomics also explores pharmacodynamics, which is the study of a drug's impact on the body. Drugs often work by interacting with specific drug targets. This interaction can inhibit or potentiate the target's activity. In oncology, many targeted therapeutics are designed to address somatic mutations in these targets. For instance, EGFR inhibitors like gefitinib or erlotinib are only used for patients with specific mutations to the EGFR gene. Genetic changes in these targets can also be germline mutations, which are inherited. A well-known example is the interaction between the drug warfarin and the VKORC1 gene. Warfarin inhibits the VKOR enzyme, which is vital for the vitamin K cycle and blood coagulation.

Sometimes, drugs can have unintended effects at "off-target" sites. This happens when a medication or its metabolites interact with a site other than the intended target. Genetic variation at these off-target sites can cause significant health issues. One notable example involves the enzyme glucose-6-phosphate-dehydrogenase, or G6PD. This enzyme is part of a pathway that helps protect cells from oxidative stress. In people with a G6PD deficiency, cells are more vulnerable to damage. If these individuals take certain medications with oxidative effects, they face a high risk of erythrocyte lysis, which leads to hemolytic anemia.

There is a distinction between pharmacogenetics and pharmacogenomics. While the terms are often used interchangeably, they describe different scopes of study. Pharmacogenetics is limited to monogenic phenotypes, which involve interactions with a single gene. In contrast, pharmacogenomics refers to polygenic drug response phenotypes. This broader field encompasses other scientific areas like transcriptomics, proteomics, and metabolomics. This allows for a much more complex understanding of how many different biological layers work together to influence a person's health and their reaction to a specific chemical compound.

Several organizations work to make this science useful in hospitals. The Clinical Pharmacogenetics Implementation Consortium, or CPIC, is an international group that creates evidence-based guidelines. These guidelines help clinicians understand how to use genetic test results to optimize drug therapy. In the United States, the FDA also provides resources like the Table of Pharmacogenetic Associations. This table helps prescribers identify subgroups of patients who might have altered drug metabolism. Additionally, the NIH-funded PharmGKB resource collects and shares knowledge about how genetic variation affects medication response. These tools help ensure that medicine is safer and more effective for everyone.

Pharmacogenomics challenges from research to practice
Pharmacogenomics challenges from research to practice
CPIC Term Consensus Table
CPIC Term Consensus Table
729 words

Where will your curiosity go next?

Keep exploring at your chosen reading level.

🖼️ Images & Media (2)
File:CPIC_Term_Consensus_Table.jpg
CPIC_Term_Consensus_Table.jpg
File:Pharmacogenomics challenges from research to practice.jpg
Pharmacogenomics challenges from research...
More to explore

🔬 Go deeper

More advanced topics to explore

🪜 Step back

Simpler topics to build understanding

What is Nepedia?

A free, ad-free encyclopedia for children. Every article is written at five reading levels, so the same page works for a five-year-old and a fifteen-year-old — use the level switcher above to see this one change. No account needed to read.